PHARVARIS NV

Insider glassman’s $32.00 purchase signals confidence in Pharvaris NV’s B2 antagonist pipeline and rising market momentum, hinting at future upside for investors.

Pharvaris CEO Modig’s recent modest share sales show disciplined liquidity planning, not a lack of confidence, as the company’s B2‑receptor pipeline fuels upside potential.

Pharvaris NV insider sales reveal a strategic shift—executives liquidating shares while the biotech navigates clinical milestones, market access, and competitive pressure in the β₂‑receptor antagonist space.

Pharvaris CEO Modig sells 2,292 shares at €34.97 under a 10‑b‑5 plan, a routine move that signals liquidity management amid a strong growth pipeline and positive market sentiment.

Pharvaris NV insiders sell shares amid strong Phase IIb data for an oral β2‑receptor antagonist, and EMA’s provisional approval signals a promising future for chronic respiratory therapy.

Pharvaris insider sales trend: CEO Modig’s routine June 2,191‑share sale shows disciplined liquidity management, not a signal of strategic shift, but a possible take‑profit trend for investors to watch.

Pharvaris insider sales show routine liquidity moves, not loss of confidence—evaluate the clinical‑stage B2 antagonist pipeline for long‑term upside.

Pharvaris NV insider trades reveal a strategic mix of buying at €8.05, selling at €29.32 and holding 25,167 shares—showing confidence in β2‑antagonist breakthroughs and market momentum.

Pharvaris NV insider trading reveals CEO liquidity moves—yet the firm’s strong B2 antagonist pipeline and outcome‑based pricing strategy keep long‑term prospects bright.

Pharvaris NV insiders buy at discount, sell at premium and liquidate options—showing bullish confidence in its B₂‑receptor pain drugs and upcoming regulatory approvals.